Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Androgen Antagonists
Antineoplastic Combined Chemotherapy Protocols
Databases, Factual
Humans
Kallikreins
Male
Middle Aged
Neoplasm Metastasis
Neoplasms, Hormone-Dependent
Prostate-Specific Antigen
Prostatic Neoplasms
Randomized Controlled Trials as Topic
Retrospective Studies
Time Factors
Treatment Outcome

authors with profiles

Daniel H. Shevrin